Definium Therapeutics, Inc. 8-K

What Happened Definium Therapeutics, Inc. (DFTX) filed an 8-K on April 22, 2026 to announce clinical and commercial updates presented at its Investor and Analyst Day. The company issued a press release and posted the related presentation to its website the same day; both documents are incorporated by reference in the filing.

Key Details

• Press release dated April 22, 2026 was attached as Exhibit 99.1 to the 8-K.
• Investor & Analyst Day presentation dated April 22, 2026 was filed as Exhibit 99.2 and posted on the company website.
• The 8-K was signed on behalf of Definium by CEO Robert Barrow on April 22, 2026.
• Item reported under 8.01 (Other Events); exhibits listed under 9.01.

Why It Matters This filing provides investors direct access to the company’s latest clinical and commercial progress and corporate messaging from management. The posted press release and presentation are primary sources for any updates on product development, trial data, timelines or commercial plans announced at the Investor & Analyst Day; investors should review those exhibits for specifics before making decisions.